Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer

Ann Oncol. 2020 May;31(5):556-557. doi: 10.1016/j.annonc.2020.02.014. Epub 2020 Mar 11.

Authors

M G J van Dongen¹, M Kok²

Affiliations

¹ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
² Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: m.kok@nki.nl.

PMID: 32171753
DOI: 10.1016/j.annonc.2020.02.014

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / drug therapy
Chemotherapy, Adjuvant
Humans
Neoadjuvant Therapy
Treatment Outcome
Triple Negative Breast Neoplasms* / drug therapy